U.S. markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.0900-0.0800 (-2.52%)
At close: 01:00PM EST
3.2400 +0.15 (+4.85%)
After hours: 03:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.1700
Bid3.0000 x 800
Ask3.1100 x 1200
Day's Range3.0000 - 3.1700
52 Week Range2.6000 - 11.9200
Avg. Volume845,288
Market Cap512.554M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ATAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ATAI Life Sciences N.V.
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

    NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH). The study will utilize a neuroimaging method to identify neuroplasticity biomarkers in patients with treatment-resistant depression (TRD) undergoing intravenous (IV) ketamine treatment. The main obj

  • GlobeNewswire

    atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

    Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022.Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GRX-917 (deuterated etifoxine) being developed for generalized anxiety disorder (GAD), demonstrating target engagement based on qEEG. Announced positive preliminary results of the single ascending dose (SAD) portion of the Pha

  • Business Wire

    Women in Psychedelics Announces atai as Platinum Sponsors

    TORONTO, November 04, 2022--The Women in Psychedelics Network ("WIPN" or "Network"), a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, as a platinum sponsor of the Network, through its philanthropic arm atai Im